In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • NIH-funded study shows increased prostate cancer risk from vitamin E supplements
    (Posted: 10/11/2011) - Men who took 400 international units of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The findings showed that, per 1,000 men, there were 76 prostate cancers in men who took only vitamin E supplements, vs. 65 in men on placebo over a seven-year period, or 11 more cases of prostate cancer per 1,000 men. This represents a 17 percent increase in prostate cancers relative to those who took a placebo. This difference was statistically significant and therefore is not likely due to chance.
  • Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
    (Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
  • Chemotherapy Combination Improves Survival in Elderly Lung Cancer Patients
    (Posted: 06/23/2010, Updated: 09/06/2011) - Survival can be improved in older patients with advanced non-small cell lung cancer (NSCLC) with the use of two chemotherapy drugs as opposed to a single agent.
  • Zoledronic Acid Improves Early Breast Cancer Treatment
    (Posted: 06/19/2008, Updated: 09/06/2011) - The addition of zoledronic acid (Zometa®) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
  • Cetuximab Combined with Oxaliplatin-Based Chemotherapy May Not Be Effective First-Line Treatment for Metastatic Colorectal Cancer
    (Posted: 08/30/2011) - In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer. The results were published on June 5, 2011 in The Lancet.
< Previous  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  Next >